Your monthly support provides voters the knowledge they need to make confident decisions at the polls. Donate today.
Gilead Sciences Inc.
This article is outside of Ballotpedia's coverage scope and does not receive scheduled updates. If you would like to help our coverage scope grow, consider donating to Ballotpedia.
| Gilead Sciences Inc. | |
 | |
| Basic facts | |
| Location: | Foster City, Calif. |
| Top official: | John F. Milligan, President and CEO |
| Year founded: | 1987 |
| Website: | Official website |
As of 2016, Gilead Sciences Inc. was a global biopharmaceutical company that sought to research, develop, and manufacture medicines "in areas of unmet medical need." Among its product portfolio, Gilead produced antiretroviral therapies to treat HIV/AIDS, including the brands Viread and Truvada. The company was based in Foster City, California.[1][2][3]
Background
Gilead Sciences Inc. was established in 1987 in Foster City, California. Since its formation, Gilead expanded across six continents to become one of the largest biopharmaceutical companies in the world.[1]
Gilead scientists aimed to research, develop, and manufacture medicines "in areas of unmet medical need." As of October 2016, the company produced 23 medications to treat HIV/AIDS, cancer, respiratory diseases, inflammatory conditions, liver diseases, and cardiovascular issues.[1][5][6]
Work
Lobbying
The following table displays Gilead's federal lobbying expenditures according to the Center for Responsive Politics:[7]
| Federal lobbying expenditures for Gilead Sciences Inc., 2010-2015 | ||
|---|---|---|
| Year | Total expenditures | |
| 2015 | $2,940,000 | |
| 2014 | $2,890,000 | |
| 2013 | $2,223,000 | |
| 2012 | $1,590,000 | |
| 2011 | $1,660,000 | |
| 2010 | $1,520,000 | |
Political activity
As of 2016, Gilead Sciences Inc. aimed to support its public policy priorities through participation in the U.S. political process. According to the company's website, Gilead's priorities "include furthering public health policy and scientific and health innovation."[8]
Gilead made political contributions to federal candidates through Gilead Sciences Inc. Healthcare Policy PAC, it's voluntary, employee-funded political action committee. In addition, the company made direct political contributions within legal guidelines to state and local candidates and political committees. Gilead was also a member of 501(c)(6) professional industry and trade organizations that aim to advocate for the interests of the science and pharmaceutical industries, such as the California Life Sciences Association.[8]
Ballot measure activity
Gilead took positions on ballot measures that sought to impact prescription drug pricing. The company opposed the 2016 California Drug Price Standards Initiative (Proposition 61), which proposed to regulate drug prices by requiring state agencies to pay the same prices for prescription drugs as the U.S. Department of Veterans Affairs (VA).[4]
Overview of ballot measure support and opposition
The following table details Gilead's ballot measure stances available on Ballotpedia:
| Ballot measure support and opposition for Gilead Sciences Inc. | |||
|---|---|---|---|
| Ballot measure | Year | Position | Status |
| California Proposition 61, Drug Price Standards (2016) | 2016 | Opposed[4] |  Defeated
|
| Prescription Drug Purchasing, Proposition D (November 2013) | 2013 | Opposed[9] |  Approved
|
Leadership
In October 2016, Gilead Sciences Inc. had the following leadership:[10]
- John F. Milligan, President and chief executive officer
- John C. Martin, Executive chairman
- Gregg H. Alton, Executive vice president, commercial and access operations ALA, corporate and medical affairs
- Norbert W. Bischofberger, Executive vice president, research and development and chief scientific officer
- Andrew Cheng, Executive vice president, clinical research and development operations
- William A. Lee, Executive vice president, research
- John McHutchison, Executive vice president, clinical research
- Brett Pletcher, Executive vice president and general counsel
- Martin B. Silverstein, Executive vice president, strategy
- Robin L. Washington, Executive vice president and chief financial officer
- Katie L. Watson, Executive vice president, human resources
- Taiyin Yang, Executive vice president, pharmaceutical development and manufacturing
- Kevin Young, Chief operating officer
Recent news
The link below is to the most recent stories in a Google news search for the terms Gilead Sciences Inc.. These results are automatically generated from Google. Ballotpedia does not curate or endorse these articles.
See also
- California Proposition 61, Drug Price Standards (2016)
- California 2016 ballot measures
- Healthcare policy in California
- TechNet
External links
Footnotes
- ↑ 1.0 1.1 1.2 Gilead Sciences Inc., "About us," accessed October 7, 2016
- ↑ Gilead Sciences Inc., "Contact," accessed October 7, 2016
- ↑ Gilead Sciences Inc., "HIV/AIDS," accessed October 26, 2016
- ↑ 4.0 4.1 4.2 California Fair Political Practices Commission, "November 2016 General Election," accessed October 2, 2016
- ↑ Drugs.com, "Gilead Sciences, Inc.," accessed October 7, 2016
- ↑ LinkedIn, "Gilead Sciences," accessed October 7, 2016
- ↑ Center for Responsive Politics, "Gilead Sciences," accessed October 26, 2016
- ↑ 8.0 8.1 Gilead Sciences Inc., "Political contributions," accessed October 26, 2016
- ↑ City of San Fransisco Department of Elections, "San Francisco Voter Pamphlet and Sample Ballot for November 5, 2013 election," accessed October 7, 2016
- ↑ Gilead Sciences Inc., "Senior management," accessed October 6, 2016
| |||||||
